Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction
Open Access
- 8 October 2025
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (5) , 990-1008
Abstract
Background and Purpose: Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses. However, developing selective inhibitors has proven challenging because of cross‐inhibition of other metalloproteases. Protein‐based inhibitors, such as the synthetic ADAM10 prodomain, offer potential for improved selectivity and effectiveness. Experimental Approach: A novel ADAM10 inhibitor, VTH144, was designed by modifying the ADAM10 prodomain and evaluated empirically for selectivity, efficacy and toxicity both in vitro and in vivo and by using machine learning–based modelling. Key Results: AlphaFold3 predictions confirm that the ADAM10 prodomain is highly selective for its protease and identify VTH144 as a unique ADAM10‐inhibiting peptide. Fluorescence resonance energy transfer (FRET) assays verified VTH144 as highly selective for ADAM10, sparing other metalloproteases. In a MI mouse model, we show that VTH144 applied twice, 4 and 48 h after ligation of the left ventricular descending artery (LAD), is highly effective in preserving cardiac function by reducing scar size. VTH144 significantly attenuates ADAM10‐mediated CX 3 CL1 shedding, subsequent neutrophil infiltration into the heart and IL‐1β‐driven systemic inflammation. Importantly, safety pharmacology in naïve mice revealed that ADAM10 inhibition with VTH144 lacks toxic short‐term effects in cardiac, pulmonary, hepatic or renal systems. Conclusions and Implications: Our study highlights the potential of the selective ADAM10 inhibitor VTH144 as a promising therapeutic candidate for improving cardiac function and reducing the risk of heart failure following myocardial infarction.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (CRC/TRR 205)
- Deutsche Forschungsgemeinschaft (CRC/TRR 296/1‐P10/424957847)
- Deutsche Forschungsgemeinschaft (EL 270/12‐1)
- Deutsche Forschungsgemeinschaft (EL 270/7‐3)
- Deutsche Forschungsgemeinschaft (IRTG 2251)
- Deutsche Forschungsgemeinschaft (KL 3356/2‐1)
- Deutsche Forschungsgemeinschaft (SFB1525‐B03/453989101)
- Deutsche Forschungsgemeinschaft (SFB877‐A3)
- Deutsche Forschungsgemeinschaft (WA 2586/4‐1)
- Bundesministerium für Forschung, Technologie und Raumfahrt (03INT703AB)
- Stiftung für Pathobiochemie und Molekulare Diagnostik (060.1052)
- European Regional Development Fund (100704177)
- European Regional Development Fund (100738497)
This publication has 74 references indexed in Scilit:
- UCSF ChimeraX : Tools for structure building and analysisProtein Science, 2023
- Matrix Metalloproteinases Repress Hypertrophic Growth in Cardiac MyocytesCardiovascular Drugs and Therapy, 2021
- Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?Pharmaceutical Research, 2019
- Functions of ‘A disintegrin and metalloproteases (ADAMs)’ in the mammalian nervous systemCellular and Molecular Life Sciences, 2019
- Immune responses in cardiac repair and regeneration: a comparative point of viewCellular and Molecular Life Sciences, 2018
- The metalloproteinase ADAM10: A useful therapeutic target?Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2017
- Matrix Metalloproteinases in Myocardial Infarction and Heart Failure2017
- An improved fluorescent substrate for assaying soluble and membrane-associated ADAM family member activitiesAnalytical Biochemistry, 2016
- An enzymic test for the diagnosis of viral hepatitis: The transaminase serum activitiesClinica Chimica Acta, 2006
- A High Throughput Fluorogenic Substrate for Interstitial Collagenase (MMP-1) and Gelatinase (MMP-9)Analytical Biochemistry, 1993